NASDAQ:REPL Replimune Group Q2 2025 Earnings Results & Report $21.78 -1.50 (-6.44%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$21.74 -0.04 (-0.16%) As of 11/11/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Replimune Group beat analyst earnings expectations in its Q2 2025 results, released November 12, 2024. The company reported EPS of -$0.68 versus the -$0.75 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateNovember 12, 2024TimeBefore Market OpensConference Call7:00 AM ET Replimune Group EPS ResultsActual EPS-$0.68Consensus EPS -$0.75Beat/MissBeat by +$0.07One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersReplimune Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Replimune Group Q2 2025 Earnings FAQ Did Replimune Group beat earnings estimates for Q2 2025? Replimune Group (NASDAQ:REPL) reported earnings of -$0.68 per share for Q2 2025, beating the consensus estimate of -$0.75. The report was announced on Tuesday, November 12, 2024. Replimune Group Earnings HeadlinesShort Interest Powder Kegs: 10 Stocks Bears Cannot Quit BuyingNovember 11 at 11:44 AM | benzinga.comReplimune Group, Inc. (REPL) - What Are Analysts Saying About This Stock?November 7, 2026 | americanbankingnews.comDo NOT Buy SpaceX Until You See “Mission X”A 30-year veteran who called Tesla before it soared 1,216% is spotlighting a company operating in the shadows of SpaceX. BlackRock, Morgan Stanley, JP Morgan and Goldman Sachs are reportedly loading up on its shares. He says the firm holds a breakthrough Elon Musk needs, and it has nothing to do with rockets or satellites. The CEO told employees more details on the Musk relationship are coming in the coming weeks. | StocksToTrade (Ad)How Investors May Respond To Replimune Group (REPL) Narrower Quarterly LossNovember 5, 2026 | finance.yahoo.comCramer's lightning round: Buy FedEx FreightNovember 3, 2026 | msn.comReplimune Group consensus price target increased by 14.78% to $22.44November 3, 2026 | msn.comSee More Replimune Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email. Email Address About Replimune GroupReplimune Group (NASDAQ:REPL) is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches. These programs remain investigational and are being evaluated in clinical studies. Founded in 2015, Replimune is headquartered in Woburn, Massachusetts. Its work centers on research and clinical development rather than marketed products or services.View Replimune Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
